Evidence map›Paper›PMID 31083666›Full record

ArticlePloS one2019

Optimization of florfenicol dose against Piscirickettsia salmonis in Salmo salar through PK/PD studies.

Betty San Martín, Marcela Fresno, Javiera Cornejo, Marcos Godoy, Rolando Ibarra, Roberto Vidal, Marcelo Araneda, Arturo Anadón, Lisette Lapierre

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Why vaccines fail againstFrontiers in immunology · 2022
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Betty San MartínLaboratorio de Farmacología Veterinaria, Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.ORCID 0000-0001-6460-5816
Marcela FresnoLaboratorio de Farmacología Veterinaria, Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.
Javiera CornejoLaboratorio de Inocuidad Alimentaria, Departamento de Medicina Preventiva, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.
Marcos GodoyCentro de Investigaciones Biológicas Aplicadas (CIBA), Puerto Montt, Chile.
Rolando IbarraInstituto Tecnológico del Salmón, Puerto Montt, Chile.
Roberto VidalFacultad de Medicina, Universidad de Chile, Santiago, Chile.
Marcelo AranedaBenchmark Genetics Chile, Puerto Montt, Chile.
Arturo AnadónDepartamento de Farmacología y Toxicología, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid, Spain.
Lisette LapierreLaboratorio de Inocuidad Alimentaria, Departamento de Medicina Preventiva, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.ORCID 0000-0002-8531-3246
University of Chile · CLInstituto Tecnológico del Salmón · CLSan Sebastián University · CLUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salmonid Rickettsial Septicemia (SRS) is the disease of greatest economic importance in the Chilean salmon farming industry, causing high mortality in fish during the final stage of their productive cycle at sea. Since current, commercially available vaccines have not demonstrated the expected efficacy levels, antimicrobials, most commonly florfenicol, are still the main resource for the treatment and control of this pathogen. The aim of this study was to determine the most appropriate single dose of florfenicol, administered through medicated feed, for the treatment of Piscirickettsia salmonis (P. salmonis), using pharmacokinetic/pharmacodynamic (PK/PD) models. Previously, Minimum Inhibitory Concentrations (MICs) of florfenicol were determined for 87 P. salmonis isolates in order to define the epidemiological cut-off point (COWT). The most commonly observed MIC was 0.125 μg mL-1 (83.7%). The COWT value was 0.25 μg mL-1 with a standard deviation of 0.47 log2 μg mL-1 and 0.36 log2 μg mL-1, for Normalized resistance interpretation (NRI) method and ECOFFinder method, respectively. A MIC of 1 μg mL-1 was considered the pharmacodynamic value (PD) to define PK/PD indices. Three doses of florfenicol were evaluated in fish farmed under controlled conditions. For each dose, 150 fish were used and blood plasma samples were collected at different time points (0-48 hours). PK parameters were obtained from curves representing plasma concentrations as a function of time. The results of Monte Carlo simulation indicate that at a dose of 20 mg/Kg l.w. of florfenicol, administered orally as medicated feed, there is 100% probability (PTA) of achieving the desired efficacy (AUC0-24h/MIC>125). According to these results, we suggest that at the indicated dose, the PK/PD cut-off point for florfenicol versus P. salmonis could be 2 μg mL-1 (PTA = 99%). In order to assess the indicated dose in Atlantic salmon, fish were inoculated with P. salmonis LF-89 strain and then treated with the optimized dose of florfenicol, 20 mg/Kg bw for 15 days.

Indexed as

Administration, OralAnimalsAnti-Bacterial AgentsArea Under CurveDrug Resistance, BacterialFish DiseasesFisheriesHalf-LifeMicrobial Sensitivity TestsMonte Carlo MethodPiscirickettsiaPiscirickettsiaceae InfectionsROC CurveSalmo salarThiamphenicolAnti-Bacterial AgentsflorfenicolThiamphenicol

Identifiers

PMID31083666
PMCPMC6513110
OpenAlexW2945875153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.